Also trades as: PCLO.V (TSXV) · $vol 0M
PCLOF OTC
PharmaCielo Ltd.
1W: -6.9%
1M: -23.6%
3M: -29.5%
YTD: -44.6%
1Y: +51.1%
3Y: -75.4%
5Y: -96.4%
$0.04
-0.00 (-2.78%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$3M
-25.2% ▼
5Y CAGR: -0.4%
Gross Profit
$633K
-13.4% ▼
Operating Income
-$4M
+21.5% ▲
Net Income
-$4M
+56.5% ▲
EPS (Diluted)
$-0.01
+90.0% ▲
EBITDA
-$1M
+72.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2M | $5M | $2M | $3M | $3M |
| YoY Growth | -26.7% | +172.9% | -71.0% | +125.7% | -25.2% |
| Cost of Revenue | $6M | $5M | $3M | $3M | $2M |
| Gross Profit | -$4M | $681K | -$1M | $731K | $633K |
| Gross Margin | -221.5% | 12.8% | -88.8% | 21.0% | 24.3% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $19M | $12M | $8M | $5M | $5M |
| Operating Expenses | $21M | $12M | $8M | $6M | $5M |
| Operating Income | -$25M | -$11M | -$10M | -$5M | -$4M |
| Operating Margin | -1295.3% | -215.4% | -629.2% | -140.9% | -147.9% |
| Interest Expense | $561K | $2M | $3M | $3M | $3M |
| Income Before Tax | -$27M | -$15M | -$16M | -$9M | -$4M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$27M | -$15M | -$16M | -$9M | -$4M |
| Net Margin | -1369.1% | -273.5% | -1057.1% | -262.7% | -153.0% |
| EPS (Diluted) | $-0.18 | $-0.10 | $-0.10 | $-0.05 | $-0.01 |
| EBITDA | -$25M | -$11M | -$12M | -$5M | -$1M |
| Shares Outstanding | 146M | 151M | 160M | 175M | 188M |